Glooko partners with insulin-dosing platform
By HME News Staff
Updated 9:09 AM CDT, Fri April 14, 2023
PALO ALTO, Calif. – Glooko, Inc. has entered into a partnership with Hedia, integrating its insulin dosing technology into Glooko’s diabetes management platforms for healthcare providers and people with diabetes. “We are very pleased to partner with Hedia to offer this algorithm-driven innovation for personalized healthcare for diabetes patients and their healthcare teams,” said Russ Johannesson, CEO of Glooko. “The robust clinical data supporting Hedia’s efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps. This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels.” With the Glooko platforms, patients currently have the ability to share their diabetes data with their healthcare providers, including blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. With the integration of Hedia Diabetes Assistant, people with diabetes will be able to receive bolus insulin dosing advice, which will provide personalized care and reduce the burden of manually calculating required insulin doses. The initial European launch of the integration is expected in the fourth quarter of 2023 and first quarter of 2024.
Comments